| Literature DB >> 21439033 |
Freek G Bouwman1, Baukje de Roos, Isabel Rubio-Aliaga, L Katie Crosley, Susan J Duthie, Claus Mayer, Graham Horgan, Abigael C Polley, Carolin Heim, Susan L M Coort, Chris T Evelo, Francis Mulholland, Ian T Johnson, Ruan M Elliott, Hannelore Daniel, Edwin C M Mariman.
Abstract
BACKGROUND: Proteomic technologies applied for profiling human biofluids and blood cells are considered to reveal new biomarkers of exposure or provide insights into novel mechanisms of adaptation.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21439033 PMCID: PMC3073865 DOI: 10.1186/1755-8794-4-24
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Figure 1Schematic representation of the study design
Number of protein spots/proteins that change during fasting challenge
| Fasting effect | Subject effect | Total detected spots/proteins | |
|---|---|---|---|
| Plasma proteomics | 13 | 703 | 1018 |
| PBMC proteomics | 83 | 4 | 910 |
| Platelet proteomics | 0 | 2 | 604 |
| Saliva proteomics | 1 | 69 | 208 |
| Urine proteomics | 3 | 58 | 142 |
| Rules Based Medicine | 39 | 78 | 89 |
A fasting and a between-subject effect was observed.
Protein identifications by MS/MS analysis of biofluid and blood cell proteins which were significantly increased or decreased upon extended fasting (36 h), as compared with overnight fasting (12 h)
| Sample type | Spot | Accession # | Protein identification | Fold- change | p-value | Adjusted p-value | Mascot score | Sequence Coverage % | Matched peptides |
|---|---|---|---|---|---|---|---|---|---|
| Plasma | 1 | P06727 | Apolipoprotein A-IV (ApoA4) | -1.80 | <0.001 | <0.001 | 426 | 69 | 34 |
| 2 | P00738 | Haptoglobin B chain | -1.15 | <0.001 | 0.009 | 87 | 32 | 8 | |
| 3 | P00738 | Haptoglobin B chain fragment | -1.14 | <0.001 | 0.006 | 139 | 33 | 17 | |
| 4 | P36955 | Pigment epithelium-derived factor | -1.09 | <0.001 | 0.061 | 113 | 35 | 16 | |
| 5 | P02741 | C reactive protein (CRP) | 1.42 | <0.001 | 0.061 | 74 | 17 | 6 | |
| PBMC | 6 | P52566 | Rho GDP-dissociation inhibitor 2 (RhoGDI2) | -2.78 | <0.001 | <0.001 | 63 | 23 | 4 |
| 7 | O00299 | Chloride intracellular channel protein 1 (CLIC1) | 5.30 | <0.001 | <0.001 | 73 | 23 | 4 | |
| Saliva | 8 | P01833 | Polymeric-immunoglobulin receptor (PIGR) | -3.16 | <0.001 | 0.030 | 161 | 15 | 10 |
| Urine | 9 | P02768 | Serum albumin precursor | 1.83 | 0.004 | 0.185 | 162 | 45 | 22 |
| 10 | P02768 | Serum albumin precursor | 2.02 | 0.001 | 0.056 | 152 | 32 | 16 |
Figure 2Identified proteins marked on 2D gels representing plasma (A), PBMC (B), saliva (C), urine (D) and platelets (E). The numbers refer to those used in Table 2.
Plasma proteins of which absolute levels significantly changed due to extended fasting (36 h) compared with overnight fasting (12 h), as assessed using the multiplex immunoassay (RBM)
| Protein | Accession # | Fold-change | p-value | Adjusted p-value |
|---|---|---|---|---|
| IGF-1 | P01343 | -2.72 | <0.001 | <0.001 |
| Leptin | P41159 | -2.59 | <0.001 | <0.001 |
| Erythropoietin | P01588 | -1.56 | 0.080 | 0.187 |
| IgE | n.a. | -1.54 | 0.002 | 0.013 |
| IL-8 | P10145 | -1.51 | <0.001 | 0.001 |
| MMP-3 | P08254 | -1.48 | <0.001 | <0.001 |
| Thyroid Stimulating Hormone | P01222 | -1.47 | <0.001 | <0.001 |
| Insulin | P01308 | -1.29 | <0.001 | 0.001 |
| Carcinoembryonic Antigen | P06731 | -1.29 | 0.037 | 0.116 |
| IL-1beta | P01584 | -1.19 | <0.001 | <0.001 |
| PAI-1 | P05121 | -1.19 | 0.002 | 0.013 |
| Apolipoprotein A-1 (ApoA1) | P02647 | -1.18 | 0.006 | 0.025 |
| MCP-1 | P13500 | -1.17 | <0.001 | 0.001 |
| Eotaxin | P51671 | -1.16 | 0.001 | 0.005 |
| VEGF | P15692 | -1.14 | <0.001 | <0.001 |
| IL-16 | Q14005 | -1.13 | <0.001 | 0.002 |
| EGF | P01133 | -1.12 | 0.085 | 0.190 |
| IL-18 | Q14116 | -1.12 | 0.013 | 0.048 |
| Alpha-Fetoprotein | P02771 | -1.12 | <0.001 | <0.001 |
| Fatty Acid Binding Protein | P05413 | -1.07 | 0.006 | 0.025 |
| IgA | n.a. | -1.07 | 0.043 | 0.116 |
| Factor VII (F7) | P08709 | -1.06 | 0.061 | 0.157 |
| Creatine Kinase-MB | P06732 | -1.04 | 0.075 | 0.181 |
| IL-10 | P22301 | -1.04 | 0.041 | 0.116 |
| Glutathione S-Transferase | P09211 | -1.04 | 0.010 | 0.041 |
| Tissue Factor (TF) | P13726 | -1.03 | 0.004 | 0.019 |
| Prostatic Acid Phosphatase | P15309 | -1.03 | 0.018 | 0.067 |
| Alpha-2 Macroglobulin (A2M) | P01023 | 1.02 | 0.021 | 0.072 |
| Complement 3 | P01024 | 1.02 | 0.028 | 0.092 |
| TIMP-1 | P01033 | 1.02 | 0.005 | 0.025 |
| IL-12p70 | P29459 | 1.03 | 0.038 | 0.116 |
| VCAM-1 | P19320 | 1.05 | 0.011 | 0.044 |
| Serum Amyloid P (SAP) | P02743 | 1.07 | 0.072 | 0.179 |
| Lipoprotein (a) | P08519 | 1.09 | 0.041 | 0.116 |
| MIP-1beta | P13236 | 1.09 | 0.048 | 0.127 |
| TNF-alpha | P01375 | 1.10 | 0.042 | 0.116 |
| EN-RAGE | P80511 | 1.17 | 0.085 | 0.190 |
| Ferritin | P02794 | 1.27 | <0.001 | 0.001 |
| C Reactive Protein (CRP) | P02741 | 1.55 | <0.001 | 0.002 |
n.a. = no accession #
Figure 3PCA analysis of data obtained from the multiplex immunoassay (RBM). Each color represents a different subject
Figure 4Biomarkers of extended fasting effect calculated by Random Forrest analysis. Panel A: results obtained from analysis of all proteomic data (2D and RBM). Panel B: results obtained from targeted proteomic analysis using multiplex immunoassay (RBM). The spot numbers between brackets refer to those used in Table 2. Proteins without numbers between brackets refer to those used in Table 3.
Figure 5Correlation score on cluster analysis of Heat map of the Pearsons correlations comparing fold-changes in plasma proteins after a 36 h fasting versus overnight fasting.
Figure 6Protein-protein interaction networking based on the outcome of the total dataset. Red represents a decrease and green an increase in protein levels. The size of the circle represents the fold change levels. The short protein names shown in the network refer to Table 2 and 3. Alpha-1-microglobulin (AMBP) was down-regulated and ApoA1 was up-regulated in urine, but not significantly (data not shown).